KRYSTAL BIOTECH INC
NASDAQ: KRYS (Krystal Biotech, Inc.)
Last update: 12 hours ago272.75
0.23 (0.08%)
| Previous Close | 272.52 |
| Open | 272.01 |
| Volume | 229,580 |
| Avg. Volume (3M) | 283,709 |
| Market Cap | 8,028,599,808 |
| Price / Earnings (TTM) | 39.88 |
| Price / Earnings (Forward) | 47.17 |
| Price / Sales | 20.98 |
| Price / Book | 6.58 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | 37.17% |
| Operating Margin (TTM) | 41.03% |
| Diluted EPS (TTM) | 4.18 |
| Quarterly Revenue Growth (YOY) | 94.90% |
| Quarterly Earnings Growth (YOY) | 3,734.00% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 9.65 |
| Operating Cash Flow (TTM) | 138.50 M |
| Levered Free Cash Flow (TTM) | 76.74 M |
| Return on Assets (TTM) | 8.66% |
| Return on Equity (TTM) | 13.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Krystal Biotech, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.88% |
| % Held by Institutions | 104.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Soleus Capital Management, L.P. | 31 Dec 2025 | 941,059 |
| Redmile Group, Llc | 31 Dec 2025 | 677,705 |
| Bellevue Group Ag | 31 Dec 2025 | 410,323 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 371.00 (Citigroup, 36.02%) | Buy |
| 371.00 (Jefferies, 36.02%) | Buy | |
| Median | 327.00 (19.89%) | |
| Low | 284.00 (Guggenheim, 4.13%) | Buy |
| Average | 335.20 (22.90%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 281.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 25 Feb 2026 | 284.00 (4.12%) | Buy | 272.50 |
| Chardan Capital | 18 Feb 2026 | 323.00 (18.42%) | Buy | 283.29 |
| Citigroup | 18 Feb 2026 | 371.00 (36.02%) | Buy | 283.29 |
| Jefferies | 17 Feb 2026 | 371.00 (36.02%) | Buy | 287.84 |
| Goldman Sachs | 02 Feb 2026 | 327.00 (19.89%) | Buy | 282.27 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Feb 2026 | Announcement | Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |